{"id":"NCT02174432","sponsor":"Trevi Therapeutics","briefTitle":"Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis","officialTitle":"An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-08-15","primaryCompletion":"2017-09-03","completion":"2017-09-03","firstPosted":"2014-06-25","resultsPosted":"2020-10-23","lastUpdate":"2025-05-21"},"enrollment":36,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prurigo Nodularis","Nodularis Prurigo","Prurigo"],"interventions":[{"type":"DRUG","name":"nalbuphine HCl ER","otherNames":["nalbuphine"]}],"arms":[{"label":"nalbuphine HCl ER","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.","primaryOutcome":{"measure":"Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"50 weeks","effectByArm":[{"arm":"Nalbuphine HCl ER","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":36},"commonTop":[]}}